JP2010540556A - アザシチジン類似体およびその使用 - Google Patents

アザシチジン類似体およびその使用 Download PDF

Info

Publication number
JP2010540556A
JP2010540556A JP2010527140A JP2010527140A JP2010540556A JP 2010540556 A JP2010540556 A JP 2010540556A JP 2010527140 A JP2010527140 A JP 2010527140A JP 2010527140 A JP2010527140 A JP 2010527140A JP 2010540556 A JP2010540556 A JP 2010540556A
Authority
JP
Japan
Prior art keywords
integer
formula
aza
subject
nhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010527140A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540556A5 (OSRAM
Inventor
シルバーマン，ルイス
ホランド，ジェームス
サンボルト，マリト，リラント
ミフレン，フィン
エリクセン，オレ，ヘンリク
Original Assignee
マウント サイナイ スクール オブ メディシン
クラビス ファーマ エーエスエー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マウント サイナイ スクール オブ メディシン, クラビス ファーマ エーエスエー filed Critical マウント サイナイ スクール オブ メディシン
Publication of JP2010540556A publication Critical patent/JP2010540556A/ja
Publication of JP2010540556A5 publication Critical patent/JP2010540556A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2010527140A 2007-09-26 2008-09-25 アザシチジン類似体およびその使用 Pending JP2010540556A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97543707P 2007-09-26 2007-09-26
PCT/US2008/077673 WO2009042767A1 (en) 2007-09-26 2008-09-25 Azacytidine analogues and uses thereof

Publications (2)

Publication Number Publication Date
JP2010540556A true JP2010540556A (ja) 2010-12-24
JP2010540556A5 JP2010540556A5 (OSRAM) 2011-08-11

Family

ID=40511851

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010527140A Pending JP2010540556A (ja) 2007-09-26 2008-09-25 アザシチジン類似体およびその使用
JP2010527139A Pending JP2010540555A (ja) 2007-09-26 2008-09-25 アザシチジン類似体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010527139A Pending JP2010540555A (ja) 2007-09-26 2008-09-25 アザシチジン類似体およびその使用

Country Status (15)

Country Link
US (2) US8399420B2 (OSRAM)
EP (2) EP2205073A4 (OSRAM)
JP (2) JP2010540556A (OSRAM)
KR (2) KR20100072230A (OSRAM)
CN (2) CN101877964A (OSRAM)
AU (2) AU2008304380A1 (OSRAM)
BR (2) BRPI0817269A2 (OSRAM)
CA (2) CA2700207A1 (OSRAM)
IL (1) IL204690A0 (OSRAM)
MX (2) MX2010003002A (OSRAM)
NZ (2) NZ583824A (OSRAM)
RU (1) RU2488591C2 (OSRAM)
UA (2) UA99836C2 (OSRAM)
WO (2) WO2009042767A1 (OSRAM)
ZA (1) ZA201001660B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540555A (ja) * 2007-09-26 2010-12-24 マウント シナイ スクール オブ メディシン アザシチジン類似体およびその使用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497292B2 (en) * 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
HUE055911T2 (hu) 2008-05-15 2021-12-28 Celgene Corp Citidin-analógokat tartalmazó orális készítmények, és eljárások azok alkalmazására
EP2321302B1 (en) 2008-08-01 2014-10-29 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
EP2424845A4 (en) * 2009-04-27 2014-03-05 Reddys Lab Ltd Dr PREPARATION OF DECITABIN
WO2012106299A1 (en) 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
US20120264710A1 (en) * 2011-04-15 2012-10-18 Marit Liland Sandvold Systems and Methods for Detecting hENT1 Expression in Hematological Disorders
SG11201401946QA (en) 2011-11-01 2014-05-29 Celgene Corp Methods for treating cancers using oral formulations of cytidine analogs
EP2817029B1 (en) 2012-02-24 2019-07-10 Signal Pharmaceuticals, LLC Methods for treating non-small cell lung cancer using tor kinase inhibitor combination therapy
US9493500B2 (en) 2012-07-19 2016-11-15 Richard Daifuku Fluorinated pyrimidine analogs and methods of use thereof
CN105392499B (zh) 2013-04-17 2018-07-24 西格诺药品有限公司 用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
WO2015195786A2 (en) 2014-06-17 2015-12-23 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
US20190022116A1 (en) * 2014-12-26 2019-01-24 Emory University N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto
WO2017090264A1 (ja) 2015-11-27 2017-06-01 大原薬品工業株式会社 ５－アザシチジン又は其の２'－デオキシ体の５'位ジベンジル燐酸エステル
MX383757B (es) 2015-12-03 2025-03-04 Epidestiny Inc Composiciones que contienen decitabina, 5azacitidina y tetrahidrouridina y sus usos
AU2018237549B2 (en) 2017-03-20 2024-08-01 Vaccinex, Inc. Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent
MY198676A (en) 2017-06-22 2023-09-15 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
CN112513061B (zh) * 2018-04-19 2025-01-24 南方研究院 用于治疗癌症的4’-硫代-核苷酸和-核苷前药
US20230416294A1 (en) * 2020-08-10 2023-12-28 The Johns Hopkins University Decitabine analogs for immunological and oncological therapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002504068A (ja) * 1995-07-25 2002-02-05 ノルスク・ヒドロ・アーエスアー 改良された治療剤
JP2006507255A (ja) * 2002-09-24 2006-03-02 コローニス ファーマシューティカルズ インコーポレイテッド ウイルス疾患の治療のための１，３，５−トリアジン
JP2007523860A (ja) * 2003-06-20 2007-08-23 コローニス ファーマシューティカルズ インコーポレイテッド ヘテロアリール化合物のプロドラッグ
JP2010540555A (ja) * 2007-09-26 2010-12-24 マウント シナイ スクール オブ メディシン アザシチジン類似体およびその使用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE612384A (fr) * 1961-01-10 1962-05-02 Spofa Vereinigte Pharma Werke Procédé de préparation des 1-glycosyle-6-aza-uraciles
GB1050899A (OSRAM) 1963-12-22
DE2012888C3 (de) * 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
DE2122991C2 (de) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
US3984396A (en) 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US3998807A (en) * 1972-03-03 1976-12-21 Syntex (U.S.A.) Inc. Arabinofuranosyl cytosines and methods of making
US4172889A (en) * 1976-03-29 1979-10-30 The Upjohn Company Method of treating rheumatoid arthritis
US4405611A (en) * 1980-06-27 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services Bisulfite stabilization of 5-azacytidine
DE3100478A1 (de) 1981-01-09 1982-08-12 Dr. Thilo & Co GmbH, 8021 Sauerlach 5'ester von pyrimidinnucleosiden mit antiviraler wirksamkeit, verfahren zur herstellung und daraus hergestellte arzneimittel
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4981613A (en) * 1986-11-04 1991-01-01 Fuji Photo Film Co., Ltd. Laser light source
CS264456B1 (cs) 1987-08-28 1989-08-14 Piskala Alois Způsob výroby 5,6-dihydro-S-azacytidinu
CS264454B1 (cs) 1987-08-28 1989-08-14 Piskala Alois 2'-Deoxy-5,6-dihydro-5-azacytidin a způsob jeho výroby
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US4984396A (en) * 1988-08-29 1991-01-15 Uragami Fukashi Cleaning device
DE3834435A1 (de) * 1988-10-10 1990-06-13 Basf Ag Verbrueckte, wasserloesliche copolymerisate, verfahren zu ihrer herstellung und ihre verwendung
US5216142A (en) 1989-04-17 1993-06-01 Efamol Holdings Plc Anti-virals
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
DE4026265A1 (de) 1990-08-20 1992-02-27 Boehringer Mannheim Gmbh Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
DE69219236T2 (de) * 1991-02-19 1997-08-07 Fujitsu Ltd Halbleiteranordnung mit einem mit sauerstoff angereicherten gebiet und deren herstellungsverfahren
US5385912A (en) 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
DK0599968T3 (da) * 1991-08-14 2000-04-17 Procter & Gamble Pharma Oxazolidinonderivater, der er egnede som antiarytmi- og antifibrilleringsmidler
GB2260319B (en) * 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
GB9307043D0 (en) 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
DE19505168A1 (de) * 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
WO1997005143A1 (en) 1995-07-25 1997-02-13 Asahi Kasei Kogyo Kabushiki Kaisha Novel group 4 transition metal compounds
CA2229044A1 (en) * 1995-08-08 1997-02-20 Thomas Jefferson University Recombinant c-proteinase and processes, methods and uses thereof
CA2229414A1 (en) 1995-09-15 1997-03-20 Anadys Pharmaceuticals, Inc. Arylhydrazone derivatives useful as antibacterial agents
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
EP0914116B1 (en) 1996-05-22 2000-10-11 Protarga Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
JPH10158192A (ja) 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
GB2321455A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
HU224918B1 (en) * 1997-01-24 2006-04-28 Conpharma As Gemcitabine derivatives, process for their preparation and pharmaceutical compositions containing them
ES2194320T3 (es) * 1997-06-03 2003-11-16 Itochu Techno Chem Inc Sustancias naturales antivirales o antitumorales y uso de las mismas.
JP2001524486A (ja) 1997-11-25 2001-12-04 プロタルガ，インコーポレーテッド ヌクレオシド類似成分組成物およびその使用
KR20010082515A (ko) 1998-02-17 2001-08-30 우에노 도시오 아미디노 유도체 및 그 유도체를 유효 성분으로서함유하는 약제
WO2000076979A1 (de) 1999-06-09 2000-12-21 Bayer Aktiengesellschaft Pyridincarboxamide und ihre verwendung als pflanzenschutzmittel
EP1210354A1 (en) 1999-09-08 2002-06-05 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
HUP0203142A3 (en) 1999-10-15 2003-03-28 Hoffmann La Roche Benzodiazepine derivatives, process for preparation of the compounds, pharmaceutical compositions containing them and their use
US6670341B1 (en) 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
NZ533094A (en) 2001-11-21 2006-01-27 Heidelberg Pharma Gmbh Phospholipid derivatives of nucleosides as antitumoral medicaments
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6943249B2 (en) * 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
JPWO2004101593A1 (ja) 2003-05-16 2006-07-13 キッセイ薬品工業株式会社 ５’−修飾ヌクレオシド誘導体及びその医薬用途
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
AU2004311702A1 (en) 2003-12-19 2005-07-21 Koronis Pharmaceuticals, Inc. Mutagenic heterocycles
WO2005066162A1 (en) 2003-12-23 2005-07-21 Human Biomolecular Research Institute Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer
CA2555311A1 (en) 2004-02-04 2005-08-18 Neurosearch A/S Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
WO2005115410A2 (en) 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
GB0419416D0 (en) 2004-09-01 2004-10-06 Inst Of Ex Botany Ascr 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof
US20060063735A1 (en) * 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
WO2006048771A1 (en) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
EP1937283A2 (en) * 2005-09-19 2008-07-02 Celator Pharmaceuticals, Inc. Combination formulations of cytidine analogs and platinum agents
ES2625378T3 (es) 2005-09-27 2017-07-19 Shionogi & Co., Ltd. Derivado de sulfonamida que tiene actividad antagonista del receptor de PGD2
NO324263B1 (no) 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
US20070225248A1 (en) * 2006-03-21 2007-09-27 Clavis Pharma As Oral dosage forms of gemcitabine derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002504068A (ja) * 1995-07-25 2002-02-05 ノルスク・ヒドロ・アーエスアー 改良された治療剤
JP2006507255A (ja) * 2002-09-24 2006-03-02 コローニス ファーマシューティカルズ インコーポレイテッド ウイルス疾患の治療のための１，３，５−トリアジン
JP2007523860A (ja) * 2003-06-20 2007-08-23 コローニス ファーマシューティカルズ インコーポレイテッド ヘテロアリール化合物のプロドラッグ
JP2010540555A (ja) * 2007-09-26 2010-12-24 マウント シナイ スクール オブ メディシン アザシチジン類似体およびその使用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540555A (ja) * 2007-09-26 2010-12-24 マウント シナイ スクール オブ メディシン アザシチジン類似体およびその使用

Also Published As

Publication number Publication date
US8158605B2 (en) 2012-04-17
NZ583824A (en) 2012-06-29
MX2010003002A (es) 2010-07-05
EP2205073A1 (en) 2010-07-14
RU2010116274A (ru) 2011-11-10
EP2197274A1 (en) 2010-06-23
CN101815437A (zh) 2010-08-25
US8399420B2 (en) 2013-03-19
EP2205073A4 (en) 2013-03-06
AU2008304381A1 (en) 2009-04-02
UA99308C2 (ru) 2012-08-10
JP2010540555A (ja) 2010-12-24
RU2488591C2 (ru) 2013-07-27
NZ583923A (en) 2012-05-25
WO2009042766A1 (en) 2009-04-02
IL204690A0 (en) 2010-11-30
CN101877964A (zh) 2010-11-03
RU2010116154A (ru) 2011-11-10
AU2008304380A1 (en) 2009-04-02
CA2700207A1 (en) 2009-04-02
UA99836C2 (en) 2012-10-10
KR20100102092A (ko) 2010-09-20
US20090209477A1 (en) 2009-08-20
KR20100072230A (ko) 2010-06-30
BRPI0817269A2 (pt) 2014-10-07
US20090209482A1 (en) 2009-08-20
EP2197274A4 (en) 2013-03-06
MX2010003261A (es) 2010-08-18
ZA201001660B (en) 2011-05-25
WO2009042766A9 (en) 2009-05-28
WO2009042767A1 (en) 2009-04-02
CA2700267A1 (en) 2009-04-02
BRPI0817234A2 (pt) 2014-09-30

Similar Documents

Publication Publication Date Title
US8399420B2 (en) Azacytidine analogues and uses thereof
US12239655B2 (en) Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents
RU2168995C2 (ru) Фармацевтические композиции, соединения, способы получения соединений
JP7558963B2 (ja) 修飾されたマイクロｒｎａ及びがんの処置におけるその使用
JP2011527678A (ja) 抗癌活性を有する２−デオキシ単糖の新規なアセテート
US10500224B2 (en) Mutual prodrug comprising short chain fatty acids and zebularine or 1'-cyano-cytarabine for cancer treatment
JPWO2019160127A1 (ja) Ｄｎｍｔ阻害剤の用途
CN114423438A (zh) Dnmt抑制剂的用途
CN101355969A (zh) 包含cyc-682和细胞毒性药物的抗增殖性组合
RU2487883C2 (ru) Аналоги азацитидина и их применение
JP6431520B2 (ja) フッ化ピリミジン類縁体及びその使用方法
US20060217345A1 (en) Beta-L-nucleosides and use thereof as pharmaceutical agents for the treatment of viral diseases
JP2019506434A (ja) ２’，２’−ジフルオロ−５−アザ−２’−デオキシシチジンまたはそれらのプロドラッグを有するｔｐ５３野生型腫瘍の治療方法
US9493500B2 (en) Fluorinated pyrimidine analogs and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110623

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130621

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131219